Table 1.
Phase III mCRPC.
| Study | Agents | n | Indication | HR (95% CI) | OS |
|---|---|---|---|---|---|
| Tax-327 [6] | Docetaxel + P vs Mitoxantrone + P | 1006 | mCRPC | 0.76 (0.62–0.94) | 18.9 vs. 16.5 |
| D9901 and D9902 [27], [28] | Sipuleucel T vs. Po | 225 | mCRPC pre docetaxel | 1.5 (1.10–2.05) | 32.2 vs. 18.9 |
| IMPACT [29] | Sipuleucel T vs. Po | 512 | mCRPC pre docetaxel | 0.78 (0.61–0.98) | 25.8 vs. 21.7 |
| COU-AA-301 [17] | Abiraterone + P vs. P | 1195 | mCRPC post docetaxel | 0.65 (0.54–0.77) | 14.8 vs. 10.9 |
| COU-AA-302 [18], [19] | Abiraterone + P vs. p | 1088 | mCRPC pre docetaxel | 0.75 (0.61–0.93) | NR vs. 27.2 |
| AFFIRM [22] | Enzalutamide vs. Po | 1199 | mCRPC post docetaxel | 0.63 (0.53–0.75) | 18.4 vs. 13.6 |
| PREVAIL [23] | Enzalutamide vs. Po | 1717 | mCRPC pre docetaxel | 0.71 (0.60–0.84) | 32.4 vs. 30.2 |
| TROPIC [24] | Cabazitaxel + P vs. Mitoxantrone + P | 755 | mCRPC post docetaxel | 0.70 (0.59–0.83) | 15.1 vs. 12.7 |
| ALSYMPCA [30] | Radium-223 vs. Po | Po921 | mCRPC pre docetaxel | 0.7 (0.55–0.88) | 14 vs. 11.2 |
| FIRSTANA [25] | Cabazitaxel 25 mg/m2 (C25) vs. 20 mg/m2 (C20) vs. docetaxel 75 mg/m2 (D75) | 1168 | mCRPC pre docetaxel | C20 vs. D75 1.01 (0.85–1.20) C25 vs. D75 0.97 (0.82–1.16) |
24.5 C20 25.2 C25 24.3 D75 |
| PROSELICA [26] | Cabazitaxel 25 mg/m2 (C25) vs. 20 mg/m2 (C20) | 1200 | mCRPC post docetaxel | 1.024 | 13.4 vs. 14.5 |
HR: hazard ratio; mCRPC, metastatic castrate-resistant prostate cancer; NR, not reached; OS, overall survival; P, prednisone; Po, placebo; CI, confidence interval.